Stacey A. Cohen, MD

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.